Trial Profile

A Phase 1, Open-label, Single Dose, Parallel Group Study To Evaluate The Pharmacokinetics Of Glasdegib (Pf-04449913) In Subjects With Impaired Renal Function

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glasdegib (Primary)
Indications Acute myeloid leukaemia; Cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Solid tumours
Focus Pharmacokinetics
Sponsors Pfizer

Most Recent Events

23 Sep 2020 Results evaluating the impact of renal impairment on the pharmacokinetics of Glasdegib presented at the 2020 American College of Clinical Pharmacology Annual Meeting
21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
26 Sep 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com